Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 2

Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 1

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &

argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that A

August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--FBRX, LXFR, SMTI,

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Barclays analyst Etzer Darout downgrades Forte Biosciences (NASDAQ:FBRX) from Overweight to Equal

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

NEW YORK, July 27, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Ass

Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consume

Global immunology pioneer Argenx SE (NASDAQ:ARGX) on Monday struck a definitive agreement to purchas

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expa

2:50pm: Market movers Forte Biosciences (NASDAQ:FBRX) shares jumped after argenx agreed to acquire t

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and tec

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc.

Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a discip

Barclays analyst Etzer Darout initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Overwe

Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular s

Dow Jones index up 50 points, Equipmentshare.Com up 15.4% on revenue guidance increase and share rep

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular

Forte Biosciences reported positive Phase 1b vitiligo data, with FB102 showing significant facial re

U.S. stocks higher, Dow gains over 150 points. NASDAQ up 0.84%, S&P 500 up 0.60%. Tech shares ju

U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers in

Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24FB102-Treate

Forte Biosciences, Inc.$500,000,000Common StockPreferred StockDebt SecuritiesDepositary SharesWarran

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.24) per share which missed the anal

U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sa

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimm

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.45) per share which missed the anal

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Forte Biosciences (NASDAQ:FB

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.99) per share which beat the analys

Additional data continues to support highly differentiated profile for FB102 in celiac diseaseForte

Guggenheim analyst Yatin Suneja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy